• Company
• Can we expect Darzalex to receive expanded reimb this year?
• by Eo, Yun-Ho Feb 19, 2024 05:45am

• Company
• Administration cycle restriction on Xospata will be lifted
• by Eo, Yun-Ho Feb 19, 2024 05:44am

• Company
• Keytruda sales expected to surpass 300 billion won
• by Nho, Byung Chul Feb 16, 2024 06:25am

• Company
• Sobi, Handok’s partner has built competitive pipelines
• by Son, Hyung-Min Feb 16, 2024 06:03am

• Policy
• Hanmi launches Zytiga generic combo after first generic
• by Lee, Tak-Sun Feb 16, 2024 06:00am

• Company
• GI makes bid with its new anticancer drug as combo therapy
• by Son, Hyung-Min Feb 16, 2024 06:00am

• Policy
• MFDS will inspect growth hormones and cold chains this year
• by Lee, Hye-Kyung Feb 16, 2024 05:59am

• Company
• Booming atopic dermatitis market, Adtralza nears reimb
• by Eo, Yun-Ho Feb 16, 2024 05:59am

• Policy
• ‘Trelegy 200 Ellipta’ concludes negotiations with the NHIS
• by Lee, Tak-Sun Feb 15, 2024 05:59am

• Company
• ‘Concerned about Korea’s stroke treatment system’
• by Son, Hyung-Min Feb 15, 2024 05:58am